Pancreatic cancer patients with BRCA mutation may benefit from targeted drug

June 15, 2018, University of Arizona

A physician-scientist at the University of Arizona Cancer Center investigated a novel treatment for pancreatic cancer patients whose tumors exhibited a harmful genetic mutation.

The results, in which a type of drug called a PARP inhibitor showed early promise in treating in patients with mutations in the BRCA gene, were published online last month in the Journal of Clinical Oncology Precision Oncology.

Rachna Shroff, MD, the UA Cancer Center's new section chief of gastrointestinal medical oncology and the study's principal investigator, said, "There are two combination chemotherapies that are approved for treating metastatic pancreatic . Beyond that, not a lot has been proven to be successful in newly diagnosed patients."

Pancreatic cancer is predicted to become the second-deadliest cancer by 2020. In most cases, by the time the disease is diagnosed, the cancer has spread beyond the pancreas and cannot be cured with surgery. The cancer's deadliness is exacerbated by a dearth of treatment options.

Pancreatic cancer often is treated with a regimen called FOLFIRINOX, a combination that includes oxaliplatin, a platinum-based chemotherapy that blocks cell division. Tumors can develop resistance to platinum therapies, however, and when traditional chemotherapy fails, few options remain.

"The new frontier for pancreatic cancer is finding ways to target pancreatic cancer outside of traditional chemotherapy," Dr. Shroff said. Whereas chemotherapy drugs use a "wrecking-ball" approach to attack cancer cells without regard to their underlying genetics, cancer researchers hope for targeted treatments that can zero in like a laser on a tumor cell's unique molecular features. As genetic analysis becomes more widespread, scientists could begin to identify different subsets of pancreatic cancers, each of which could be targeted by drugs optimized for their unique genetic profiles.

Nine percent of pancreatic cancer patients have a mutation in the BRCA gene, making them one subset that already has been identified. Under normal circumstances, BRCA keeps tumors at bay by repairing damaged DNA. However, a mutation in BRCA causes it to lose its tumor-suppressing abilities, increasing susceptibility to cancer.

"This is a very important subset," said Dr. Shroff. "I don't think we've fully understood how best to serve this population."

PARP is a protein that repairs damaged DNA in tumor cells, helping cancer to grow. Rucaparib is a PARP inhibitor, a drug that blocks PARP from repairing DNA, thereby killing cancer cells. Because it is effective in breast and ovarian cancers with the BRCA mutation, Dr. Shroff hoped to learn if it would work in pancreatic cancer patients with that mutation as well.

"Cancer cells are rapidly dividing," Dr. Shroff explained. "This inhibitor targets the enzyme that helps them rapidly divide and grow without errors in DNA replication. PARP is probably one of the few valid targets we have identified in pancreatic cancer."

The study, which Dr. Shroff led when she was at MD Anderson Cancer Center, was one of a small handful looking at the efficacy of PARP inhibitors in pancreatic cancer patients with the BRCA mutation. A total of 19 patients were enrolled. Participants had locally advanced or metastatic pancreatic cancer, and had only received one or two previous chemotherapy regimens. Some of these patients saw results. "Patients who did respond responded nicely and for a while," reported Dr. Shroff. "We had one complete response—the disease completely melted away."

Overall, 32 percent of patients experienced disease control, in which tumors either stopped growing, got smaller or disappeared. Among patients who only had received one previous chemotherapy regimen, 44 percent experienced disease control.

The fact that patients with less exposure to chemotherapy were more likely to respond to PARP inhibitors indicates that tumor cells that acquire the tools to resist platinum-based drugs also could have the skills needed to resist PARP inhibitors.

"As we started to think about the 'would have, could have, should haves,' we thought perhaps the way to design the study would be in patients who were platinum-sensitive," said Dr. Shroff.

Despite the small sample size, investigators concluded that PARP inhibitors such as rucaparib could help the subset of pancreatic cancer patients with BRCA mutations, especially those whose diseases did not worsen when on platinum-based therapy.

"This study paves the way for further studies with PARP inhibitors in with advanced pancreatic cancer and alterations in the BRCA pathway," said Dr. Shroff. "It was one of the landmark studies looking at this therapy in BRCA-mutated cancer only."

Although current research into PARP inhibitors focuses on these drugs when used alone, Dr. Shroff believes they might be better when combined with other treatments. She hopes to design trials to test the efficacy of PARP inhibitors with immunotherapy, drugs that train the body's immune system to recognize and attack cancer cells.

"Pancreatic cancer is a devastating disease with very poor survival in advanced stages," said Dr. Shroff. "It is now the third-leading cause of cancer death in the United States. Finding new treatment options is crucial."

Explore further: Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation

More information: Rachna T. Shroff et al. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation, JCO Precision Oncology (2018). DOI: 10.1200/PO.17.00316

Related Stories

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation

May 17, 2018
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

Drug combination boost PARP inhibitor response in resistant ovarian cancer

April 3, 2017
About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...

New findings may enhance PARP inhibitors therapy in breast cancer

January 18, 2016
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Novel combination therapy shown to be effective in ovarian cancer

December 19, 2017
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers ...

Recommended for you

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.